Supervisory Board of Biofrontera AG renews Management Board appointment
July 23, 2020 08:30 ET
|
Biofrontera AG
Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today...
Biofrontera shows robust growth during first six months of 2019
August 27, 2019 02:15 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera provides update on Cutanea integration
August 05, 2019 09:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production
January 08, 2019 02:02 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that...
Biofrontera to Participate in Two Upcoming Investor Conferences
November 26, 2018 13:08 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...
Biofrontera uses the long summer months to introduce daylight photodynamic therapy (PDT) with Ameluz® in the EU
September 17, 2018 05:17 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced an update on...
Correction of news release from August 31, 2018: Biofrontera reports significant revenue growth for the first 6 months of 2018
September 03, 2018 05:35 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...